Free Trial
NASDAQ:ARDX

Ardelyx Q2 2025 Earnings Report

Ardelyx logo
$4.49 -0.21 (-4.47%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.40 -0.09 (-2.00%)
As of 06:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.12
Beat/Miss
N/A
One Year Ago EPS
N/A

Ardelyx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ardelyx Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Ardelyx Earnings Headlines

FY2025 EPS Estimates for Ardelyx Lifted by Cantor Fitzgerald
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
Ardelyx Secures $50 Million Loan Amendment
See More Ardelyx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email.

About Ardelyx

Ardelyx (NASDAQ:ARDX) is a clinical-stage biopharmaceutical company headquartered in Fremont, California, dedicated to developing and commercializing novel treatments for patients with kidney and gastrointestinal diseases. Since its founding in 2004, Ardelyx has focused on therapies that target the underlying mechanisms of disease by modulating ion transport in the gut and kidneys. The company’s research efforts have led to the identification of innovative small-molecule candidates designed to address significant unmet medical needs in chronic kidney disease (CKD) and related metabolic disorders.

The company’s first approved therapy, XPHOZAH™ (tenapanor), received U.S. Food and Drug Administration approval in December 2021 for the control of serum phosphorus in adult patients with CKD on dialysis. Tenapanor acts by inhibiting the gastrointestinal sodium/hydrogen exchanger NHE3, reducing intestinal phosphate absorption. Beyond this indication, Ardelyx is advancing tenapanor through late-stage clinical trials in patients with irritable bowel syndrome with constipation (IBS-C) and exploring its use in CKD patients not yet requiring dialysis. In addition to tenapanor, Ardelyx has several early-stage programs, including novel compounds aimed at restoring electrolyte balance and improving gastrointestinal motility.

Ardelyx operates primarily in the United States but maintains collaborative partnerships to extend its reach globally. The company has entered into strategic alliances with pharmaceutical and biotechnology firms to support clinical development, regulatory submissions, and commercialization in key markets. These collaborations leverage Ardelyx’s expertise in ion transport biology alongside partners’ commercial infrastructure and regulatory experience, with the goal of delivering innovative therapies to patients worldwide.

The company is led by a seasoned management team with deep experience in biopharmaceutical research and commercialization. Chris Boerner, President and Chief Executive Officer, brings more than two decades of leadership in specialty pharmaceuticals, supported by a cadre of scientific, medical, and regulatory professionals. Ardelyx’s board and executive committee guide its strategy with a commitment to advancing science, maintaining rigorous safety standards, and ultimately improving the lives of patients suffering from kidney and gastrointestinal disorders.

View Ardelyx Profile

More Earnings Resources from MarketBeat